Entera Bio Ltd. (NASDAQ: ENTX) announced on July 31, 2026, that its Chief Executive Officer, Miranda Toledano, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference. The event provides investors and analysts with an opportunity to discuss the company’s clinical-stage pipeline of oral peptide and protein replacement therapies, including its most advanced candidate, EB613, for osteoporosis.

The fireside chat is scheduled for August 12, 2026, at 1:00 p.m. Eastern Time. The broader conference will take place from August 11–13, 2026, at the InterContinental Boston Hotel, located at 510 Atlantic Avenue in Boston, Massachusetts. In addition to the public session, Toledano will hold one-on-one meetings with investors during the event.

A live webcast of the discussion, including presentation slides, will be accessible via the company’s designated link. A replay of the session will remain available for 365 days following the event, allowing stakeholders who cannot attend in person to review the proceedings.

Conference Details

Entera Bio is a clinical-stage company leveraging its proprietary N-Tab technology platform to develop first-in-class oral peptide programs. The company’s lead product candidate, EB613 (oral PTH(1-34)), is being developed as a once-daily tablet for osteoporosis. A placebo-controlled, dose-ranging Phase 2 study involving 161 patients met both primary (PD/bone turnover biomarker) and secondary (BMD) endpoints.

The company’s pipeline also includes EB612, an oral Long Acting PTH(1-34) tablet for hypoparathyroidism; an oral oxyntomodulin tablet targeting obesity and metabolic syndromes; and an oral GLP-2 tablet for short bowel syndrome, developed in collaboration with OPKO Health, Inc. These programs aim to provide oral alternatives to injectable therapies for significant unmet medical needs.

What the Numbers Show

While this announcement does not disclose new financial metrics, it highlights Entera Bio’s focus on advancing its clinical pipeline through investor engagement. The successful Phase 2 results for EB613, which met primary and secondary endpoints in a trial of 161 patients, underscore the potential of its oral peptide platform. The upcoming conference serves as a key milestone for communicating progress on these candidates to the market ahead of further clinical developments.

Entera Bio Ltd. (NASDAQ: ENTX) shares rebounded Wednesday after the company announced an oversubscribed private placement expected to raise approximately $275 million. The capital injection is designed to fully fund Phase 3 registrational studies for EB613, its lead oral PTH(1-34) peptide tablet for osteoporosis, and extend the company’s cash runway into 2030. Investors weighed the significant liquidity boost against dilution concerns from the large securities issuance, driving the stock higher despite broader market headwinds.

The financing involves the sale of approximately 122.96 million ordinary shares and pre-funded warrants covering up to 11.84 million shares. Entera priced the ordinary shares at $2.04 each, with warrants priced at $2.04 minus their nominal exercise price. The gross proceeds of $275 million are stated before the deduction of placement agent fees and other offering expenses.

Investor Participation and Governance

Existing investor BVF Partners L.P. led the financing, alongside Longitude Capital, Vivo Capital, TCGX, RA Capital Management, Perceptive Advisors, Spruce Street Capital, Venrock Healthcare Capital Partners, Driehaus Capital Management, Logos Capital, Catalio Capital Management, and other investors. Following the closing, BVF will gain the right to designate two directors to Entera’s board, subject to applicable requirements.

Market Reaction and Technical Outlook

Entera Bio stock traded at elevated levels, reaching $3.20, significantly above its 20-day simple moving average (SMA) of $2.07. The Relative Strength Index (RSI) hit 70.83, signaling overbought conditions. Key resistance sits at $4.20, the 52-week high, while support aligns with the 20-day SMA at $2.07. At the time of publication, shares were up 0.31% at $3.27.

Financial Outlook

Analysts project Entera Bio will report a loss of eight cents per share when earnings are released on Aug. 11, wider than the six cents loss previously reported, with no revenue expected. HC Wainwright maintains a Buy rating with a price target of $9.

What the Numbers Show

The oversubscribed nature of the $275 million raise indicates strong institutional confidence in EB613’s commercial potential. By securing funds through 2030, Entera mitigates near-term dilution risks associated with frequent fundraising, allowing management to focus on clinical execution for its lead asset.